摘要【目的】观察氟伐他汀联合缬沙坦治疗糖尿病肾病（DN）患者的临床疗效及对内皮素-1（ET-1）和降钙素基因相关肽（CGRP）的影响。【方法】将70例DN患者随机分为观察组和对照组，每组35例；在常规治疗的基础上，观察组给予氟伐他汀联合缬沙坦治疗，对照组给予缬沙坦治疗；3个月后分析比较两组患者的24 h尿蛋白定量和血中ET-1、CGRP水平、临床总有效率及不良反应发生情况。【结果】两组患者的24 h尿蛋白定量和血中ET-1水平均较治疗前降低，血中CGRP水平均较治疗前升高，差异有统计学意义（ P ＜0．05或 P ＜0．01），且上述指标的改善观察组优于对照组（ P ＜0．05）；观察组的临床总有效率为91．43％，优于对照组的74．29％（ P ＜0．05）；两组不良反应发生率比较差异无统计学意义（ P ＞0．05）。【结论】氟伐他汀联合缬沙坦治疗DN安全有效，其降脂降压外的肾保护作用可能与调节血中ET-1、CGRP水平有关。
Abstract：Objective To observe the clinical efficacy of fluvastatin combined with valsartan for the treatment of pa-tients with diabetic nephropathy (DN) and its impact on endothelial-1(ET-1) and calcitonin gene related peptide(CGRP) .[Methods]Totally 70 patients with DN were randomly divided into observation group and control group with 35 cases in each .On the basis of routine treatment ,the observation group received fluvastatin combined with valsartan ,while the control group received valsartan .The 24h quantitative urinary protein ,blood levels of ET-1 and CGRP ,clinical total effi-cacy and the incidence of adverse reaction were compared between two groups after 3 months .[Results] Compared with before treatment ,the 24h quantitative urinary protein and blood ET-1 in two groups after treatment were decreased ,but blood CGRP was increased ,and there was significant difference ( P<0 .05 or P<0 .01) .The improvement of above in-dexes in observation group was better than the control group ( P<0 .05) .The clinical total effective rate of observation group was better than that of the control group (91 .43% vs .74 .29% )( P<0 .05) .There was no significant difference in the incidence of adverse reactions between two groups ( P >0 .05) .[Conclusion]Fluvastatin combined with valsartan for the treatment of DN is safe and effective .The renal protective effect except lowing blood fat and blood pressure may be related to the regulation of ET-1 and CGRP in blood .
引用本文:
侯保俊. 氟伐他汀联合缬沙坦治疗糖尿病肾病患者的疗效及对 ET-1、CGRP 的影响[J]. 医学临床研究, 2014, 31(7): 1303-1305.
HOU Bao-j un. Efficacy of Fluvastatin Combined with Valsartan for the Treatment of Patients with Diabetic Ne-phropathy and Its Impact on ET-1 and CGRP. 医学临床研究, 2014, 31(7): 1303-1305.
2014, Vol. 31 
